en · de · es · fr · pt
selank-notes.peptides5388.com › Topic › Background And Peptide Identity — Practical Notes

Background And Peptide Identity — Practical Notes

By Editorial Desk · published 2025-10-30 · last reviewed 2025-12-03 · Topic

Everything below concerns tuftsin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-12-03. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Peptide Identity

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Peptide Identity and Structure

The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideModeled on tuftsin
Amino acid sequenceThr-Lys-Pro-Arg-Pro-Gly-ProSeven residues
Approximate molecular massAround 750 DaDepends on counter-ion and hydration
Common formsLyophilized powderAlso described as aqueous solution
Primary origin of researchRussian laboratoriesMid-1990s onward

Selank Background And Chemical Identity

Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Related pages on this site

Storage, Analysis, and Regulatory Status

Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.

Reference notes

Anaroids (アーナロイド, Ānaroido): Asteroid-themed androids that wield blasters and swords. The Anaroids are voiced by Katsumi Shiono (塩野 勝美, Shiono Katsumi) and Yuuki Anai (穴井 勇輝, Anai Yūki). Batsuroids (バーツロイド, Bātsuroido): Planet-themed androids that lead the Anaroids and wield hand-mounted guns and, later, swords. Throughout the series, the Batsuroids pilot Kaijuki such as the chest of drawers-themed Super Kaijuki (超巨大怪重機, Chōkyodai Kaijūki) Big Drawer (ビグドローワー, Bigu Dorōwā), which is capable of storing buildings, the flight-capable Hunter Jet 2 (ハンタージェット2, Hantā Jetto Tsū), the angel-themed Megaroria (メガロリア), and the knight-themed Knight Chaser (ナイトチェイサー, Naito Cheisā) before being destroyed by Deka Base Robo, confiscated by the Dekarangers for use in a sting operation, destroyed by Deka Bike Robo, and destroyed by Super Dekaranger Robo respectively. The Batsuroids are voiced by Katsumi Shiono and Yuuki Anai. Igaroids (イーガロイド, Īgaroido): Star-themed androids that are able to speak human languages, lead the Anaroids and Batsuroids, and primarily wield swords that allow them to perform the Cross Burst (クロスバースト, Kurosu Bāsuto) attack. The Igaroids are voiced by Kazuya Nakai (中井 和哉, Nakai Kazuya).

== Key people == The Santa Monica-based startup was founded in September 2011 by Trevor Bezdek and former Facebook executives Doug Hirsch and Scott Marlette. Marlette was one of the first 20 employees at Facebook and built Facebook's photo application. In 2005, Hirsch was the Vice President of Product at Facebook, working closely with Mark Zuckerberg. Bezdek and Hirsch served as co-chief executive officers until April 2023, when they stepped down from those roles and technology executive Scott Wagner was appointed interim chief executive officer. Bezdek became chair of the board, while Hirsch took on the role of chief mission officer. In December 2024, GoodRx announced that healthcare executive Wendy Barnes would become president and chief executive officer effective January 1, 2025. As of 2025, Barnes serves as the company's CEO, while Trevor Bezdek and Scott Wagner serve as co-chairs of the board, and Doug Hirsch remains involved as a co-founder and senior executive.

== Toxicological experiments == During the 1980s the Philip Morris Tobacco Company carried out research on sidestream smoke at the Institut für Biologische Forschung, although this was not voluntarily published. This study found that sidestream smoke is nearly four times more toxic than mainstream smoke per metric gramme. They also found that sidestream condensate was nearly three times more toxic than mainstream smoke as well as 2–6 times more tumourigenic per gram than mainstream condensate when applied to the skin of a mouse; results also showed that sidestream smoke hinders an animal's ability to reach a weight that is considered normal. The research team concluded that the only way to protect oneself from sidestream smoke was to be in smoke-free public places and workspaces.

=== Alphabet methods === A special class of protein structural alignment programs convert the input structure into a sequence of letters describing the structure. This allows methods from sequence alignment to be translated into this field to enable more efficient searching, and in some implementations, to also align and superimpose in real 3D space.

Sources: en.wikipedia.org

Reference notes

== Diagnosis == The diagnosis of a migraine is based on signs and symptoms. A headache calendar is a useful diagnostic tool for tracking the date, duration, and symptoms of headaches. Migraines can be classified by whether the patient experiences an aura (MA) or not (MO) and headache frequency (episodic or chronic). According to the International Classification of Headache Disorders (ICHD-3), migraine diagnosis is primarily clinical and based on identifying characteristic patterns of headache features and associated symptoms rather than laboratory or imaging findings. Neuroimaging tests are not necessary to diagnose migraine, but may be used to find other causes of headaches in those whose examination and history do not confirm a migraine diagnosis. The American Headache Society's guideline recommends neuroimaging only when "red-flag" symptoms or abnormal neurological findings are present, noting that routine imaging is unnecessary for patients who already meet clinical criteria for migraine. The diagnosis of migraine without aura, according to the International Headache Society, can be made according to the "5, 4, 3, 2, 1 criteria", which is as follows:

While contemporary models, such as the Big Five or psychometric adaptations such as Hans Eysenck's PEN model, often define these terms through social behavioural traits (such as shyness, gregariousness, sociability and impulsivity), Jung defined them as 'directional orientations of libido.' Modern theories often stay true to behaviourist means of describing such a trait (sociability, talkativeness, assertiveness etc.), whereas Jungian introversion and extraversion are expressed as a perspective: introverts interpret the world subjectively, whereas extraverts interpret the world objectively. Jung also posited different functions of consciousness: two perceiving/non-rational functions: sensation and intuition; and two judging/rational functions: thinking and feeling. These are modified (or combined with) the two main attitudinal types (introversion and extroversion) to produce eight distinct psychological types: extraverted sensing, introverted sensing, extraverted intuiting, introverted intuiting, extraverted thinking, Introverted thinking, extraverted feeling, and introverted feeling. Whilst Jung posits these different types, he argues that it is rare that a person is an absolutely 'pure' type, and more likely a person has a main function, but also has a secondary function which blurs the picture. The secondary type is known as the 'inferior type' and is often associated with the shadow.

However the studies purporting its benefit use abnormally high doses in the millimolar range (similar to the extracellular potassium concentration), which are unlikely to be achieved in humans. BAY 11-7082 has also been identified as a drug that can inhibit the NF-κB signaling cascade. It is capable of preventing the phosphorylation of IKK-α in an irreversible manner such that there is down regulation of NF-κB activation. It has been shown that administration of BAY 11-7082 rescued renal functionality in diabetic-induced Sprague-Dawley rats by suppressing NF-κB regulated oxidative stress. Research has shown that the N-acylethanolamine, palmitoylethanolamide is capable of PPAR-mediated inhibition of NF-κB. The biological target of iguratimod, a drug marketed to treat rheumatoid arthritis in Japan and China, was unknown as of 2015, but the primary mechanism of action appeared to be preventing NF-κB activation.

clinafloxacin gatifloxacin moxifloxacin sitafloxacin prulifloxacin besifloxacin delafloxacin Two structurally related fourth-generation drugs, but formally not 4-quinolones, are gemifloxacin and trovafloxacin (removed from clinical use). In development:

=== Combination hemoglobinopathies === A combination hemoglobinopathy occurs when someone inherits two different abnormal hemoglobin genes. If these are different versions of the same gene, one having been inherited from each parent it is an example of compound heterozygosity. Both alpha- and beta- thalassemia can coexist with other hemoglobinopathies. Combinations involving alpha thalassemia are generally benign. Some examples of clinically significant combinations involving beta thalassemia include:

Sources: en.wikipedia.org

Frequently asked questions

What type of molecule is Selank?

Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.

Where was Selank developed?

It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.

Is Selank found in nature?

No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.

What is the primary sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.

Network